Bristol Myers' Opdivo steps in FDA fast lane for potential first-in-class nod in pre-surgery lung cancer

As immuno-oncology agents gradually move in to treat earlier stages of diseases, Bristol Myers Squibb has earned a regulatory boost that could potentially make it the first company to enter a key lung cancer setting.

The FDA granted priority review for an approval application that covers Opdivo in combination with chemotherapy as a treatment prior to surgery in resectable non-small cell lung cancer (NSCLC), BMS said Monday.